Comparative effectiveness of natalizumab on cognition in multiple sclerosis: A cohort study

BACKGROUND: Cognitive impairment occurs in 40%–70% of persons with multiple sclerosis (MS). OBJECTIVE: To examine the effectiveness of natalizumab compared with other disease-modifying treatments (DMTs) on improving cognition as measured by the Symbol Digit Modalities Test (SDMT). METHODS: Data were...

Descripción completa

Detalles Bibliográficos
Autores principales: Manouchehrinia, Ali, Larsson, Hanna, Karim, Mohammad Ehsanul, Lycke, Jan, Olsson, Tomas, Kockum, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152556/
https://www.ncbi.nlm.nih.gov/pubmed/36789885
http://dx.doi.org/10.1177/13524585231153992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152556/
https://www.ncbi.nlm.nih.gov/pubmed/36789885
http://dx.doi.org/10.1177/13524585231153992

Ejemplares similares